Business Description
Bionano Genomics Inc
NAICS : 334516
SIC : 2836
ISIN : US09075F3055
Total Employee Number:
97Description
Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis, particularly optical genome mapping (OGM). Its principal platform, the Saphyr system, detects structural variations in DNA with high sensitivity and specificity, serving researchers and clinicians in cancer research, genetic disease studies, and cytogenomics. The company also offers Ionic Purification systems, consumables, and VIA software for data analysis and visualization. Bionano generates revenue primarily through product sales, including instruments, chips, reagents, and software licenses, along with service and support offerings. It operates across the Americas, EMEA, and Asia Pacific, with EMEA historically contributing the largest share of revenue. Its customers include academic and research institutions, clinical laboratories, and pharmaceutical and biotechnology companies. The company is headquartered in San Diego, California.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.48 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -22.25 | |||||
Beneish M-Score | -3.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55.1 | |||||
3-Year EBITDA Growth Rate | 77.1 | |||||
3-Year EPS without NRI Growth Rate | 74 | |||||
3-Year FCF Growth Rate | 77.6 | |||||
3-Year Book Growth Rate | -79.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 53.08 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 0.99 | |||||
Days Inventory | 145.8 | |||||
Days Sales Outstanding | 52.54 | |||||
Days Payable | 126.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -178.9 | |||||
Shareholder Yield % | -76.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.51 | |||||
Operating Margin % | -106.67 | |||||
Net Margin % | -106.58 | |||||
EBITDA Margin % | -72.06 | |||||
FCF Margin % | -67.87 | |||||
OCF Margin % | -67.87 | |||||
ROE % | -77.07 | |||||
ROA % | -47.15 | |||||
ROIC % | -71.13 | |||||
3-Year ROIIC % | -75.15 | |||||
ROC (Joel Greenblatt) % | -96.3 | |||||
ROCE % | -65.22 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.36 | |||||
PB Ratio | 0.46 | |||||
Price-to-Tangible-Book | 0.48 | |||||
EV-to-EBIT | -0.55 | |||||
EV-to-EBITDA | -0.78 | |||||
EV-to-Revenue | 0.56 | |||||
EV-to-Forward-Revenue | 0.32 | |||||
EV-to-FCF | -0.55 | |||||
Price-to-GF-Value | 1.35 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
Earnings Yield (Greenblatt) % | -182.46 | |||||
FCF Yield % | -100.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bionano Genomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 30.176 | ||
| EPS (TTM) ($) | -3.731 | ||
| Beta | 0.6359 | ||
| 3-Year Sharpe Ratio | -1.48 | ||
| 3-Year Sortino Ratio | -1.42 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 5.2545 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 5.2545 - 5.2545 | ||
| Shares Outstanding (Mil) | 11.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bionano Genomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bionano Genomics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 53 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 52 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-14 10:30 | -- | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 16:30 | -- | ||
| Second quarter earnings results for 2026 | 2026-08-10 | -- | ||
| General meeting for 2026 | 2026-05-14 10:00 | -- | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | -- | ||
| First quarter earnings results for 2026 | 2026-05-13 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-23 16:30 | -- | ||
| Annual report for 2025 | 2026-03-23 | -- |
Show
Entries
Bionano Genomics Inc Frequently Asked Questions
What is Bionano Genomics Inc(LTS:0A4K)'s stock price today?
The current price of LTS:0A4K is $5.25. The 52 week high of LTS:0A4K is $5.25 and 52 week low is $5.25.
When is next earnings date of Bionano Genomics Inc(LTS:0A4K)?
The next earnings date of Bionano Genomics Inc(LTS:0A4K) is 2026-11-13 Est..
Does Bionano Genomics Inc(LTS:0A4K) pay dividends? If so, how much?
Bionano Genomics Inc(LTS:0A4K) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers